- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/643 - 2-PhenoxypyridinesDerivatives thereof
Patent holdings for IPC class C07D 213/643
Total number of patents in this class: 172
10-year publication summary
|
11
|
6
|
7
|
9
|
10
|
10
|
4
|
13
|
8
|
7
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4642 |
6 |
| Board of Regents, The University of Texas System | 5808 |
6 |
| Autifony Therapeutics Limited | 48 |
5 |
| Pharmakea, Inc. | 36 |
5 |
| XENIOPRO GmbH | 15 |
5 |
| Purdue Pharma L.P. | 501 |
4 |
| University of Kansas | 875 |
4 |
| Bayer AG | 3325 |
3 |
| Italfarmaco SpA | 148 |
3 |
| Glaxo Group Limited | 4063 |
2 |
| Bristol-myers Squibb Company | 4880 |
2 |
| General Electric Company | 13810 |
2 |
| BASF SE | 20940 |
2 |
| Centre National de La Recherche Scientifique | 10464 |
2 |
| Bayer Pharma AG | 1053 |
2 |
| The General Hospital Corporation | 4740 |
2 |
| President and Fellows of Harvard College | 5986 |
2 |
| Takeda Pharmaceutical Company Limited | 2708 |
2 |
| Vertex Pharmaceuticals Incorporated | 1600 |
2 |
| Arizona Board of Regents Acting for and on Behalf of Arizona State University | 99 |
2 |
| Other owners | 109 |